top of page

NEWS AND MEDIA

NEWS
Xalud Therapeutics Appoints Charles Triano as Chief Financial Officer
Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing
Xalud Therapeutics Announces the Expansion of Its Strategic Advisors
MAY 20, 2021
Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas
Xalud Therapeutics Expands Leadership Team with Key Appointments
JANUARY 22, 2021
Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer
bottom of page